Clinical trial · Observational
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression
INVESTIGATING eNAMPT ROLE IN ACQUISITION OF EPITHELIAL TO MESENCHYMAL TRANSITION-LIKE FEATURES IN MULTIPLE MYELOMA
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Based on our previous observations, here the investigator plans to further investigate eNAMPT in MM biology and to establish its role in disease progression where EMT acquisition represents an hallmark of cancers. Results deriving from proposal would hopefully identify novel biological vulnerabilities of such malignancy and an innovative biomarker for disease progression monitoring as well.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (5)
- measure
- To strengthen preliminary data
- timeFrame
- 2 years
- description
- To strengthen preliminary data and to investigate the correlation between eNAMPT levels in BM and peripheral blood (PB) compartments by assessing its concentration in paired samples collected from a larger cohort of NDMM patients, using also more HDs as control.
- measure
- Potential marker of PD
- timeFrame
- 2 years
- description
- To disclose eNAMPT relevance as potential marker of disease progression by comparing eNAMPT plasmatic levels from samples collected in different phases of disease (MGUS, Smoldering Multiple Myeloma -SMM-, NDMM, relapsed/refractory MM) and by their correlation with available clinical data.
- measure
- Analysis both MM cells and MM-BMSC compartment.
- timeFrame
- 2 years
- description
- To investigate cellular source of eNAMPT production in MM by analyzing both MM cells (Established Human Myeloma Cell Lines, HMCLs and primary CD138+ cells) and MM-BMSC compartment.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Male and female patients over 18 years of age; * PB-derived serum samples collected in different disease phases (MGUS, SMM, NDMM and RRMM MM patients) * Sufficient CD138+ cells or RNA from CD138+ cells are available; * ≥ 2 years median survival data and treatment data is available (progression free and overall survival); * Bone marrow sample acquired prior to the initiation of the therapy of interest; * Patients have consented for use of their sample for research purposes.
References
Publications (0)
Data not yet available